FH535
CAS No. : 108409-83-2
| Size | Price | Stock |
|---|---|---|
| 5mg | $42 | In-stock |
| 10mg | $66 | In-stock |
| 50mg | $204 | In-stock |
| 100mg | $352 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15721 |
| M.Wt: | 361.20 |
| Formula: | C13H10Cl2N2O4S |
| Purity: | >98 % |
| Solubility: | DMSO : 33.33 mg/mL (ultrasonic) |
FH535 is an inhibitor of Wnt/β-catenin and PPAR with anti-tumor activities[1].
IC50 & Target:Wnt, β-catenin, PPAR[1]
In Vitro:FH535 is an inhibitor of Wnt/β-catenin and PPAR. FH535 inhibits PPARγ and PPARδ transactivation in HCT116 cells. FH535 (15 μM) activities depend on functional PPARδ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β-catenin to PPARδ and PPARγ. FH535 shows toxic effects on 12 carcinoma cell lines expressing wnt/β-catenin pathway[1].
FH535 (20 μM) suppresses the β-catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μM) inhibits pancreatic cancer cell invasion and cell growth[2].
FH535 represses angiogenesis-related genes in pancreatic cancer cells[3].
In Vivo:FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- FH535
- Cat. No.:
- HY-15721
- Quantity:
Your information is safe with us.